Analyst firms · Deutsche Bank · ISRG
Deutsche Bank ISRG price target and rating history
Intuitive Surgical Inc. (ISRG) · Health Care
Deutsche Bank rates Intuitive Surgical Inc. (ISRG) Sell with a $440 price target, as of its latest action on Jun 9, 2025. It has published 3 rating actions on ISRG since July 2021, including 0 upgrades and 1 downgrade. Across 7 firms with a ISRG price target in the last 12 months, the median target is $500.
- Current rating
- Sell
- Price target
- $440
- Median target, all firms
- $500
- Actions on ISRG
- 3
Deutsche Bank price target on ISRG
Every Deutsche Bank rating on ISRG
- Jun 9, 2025
- Jan 21, 2022
- Jul 22, 2021
How other firms rate ISRG
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Erste Group | Buy | Oct 21, 2026 | |
| Barclays | Overweight | $485 | Oct 7, 2026 |
| Oppenheimer | Outperform | $500 | Aug 12, 2026 |
| HSBC | Hold | $391 | Jul 30, 2026 |
| UBS | Buy | $500 | Jul 28, 2026 |
| BMO Capital Markets | Outperform | $518 | Jul 9, 2026 |
| Citigroup | Buy | $590 | Mar 11, 2026 |
| TD Cowen | Buy | $660 | Jan 27, 2026 |
Questions about Deutsche Bank and ISRG
- What is Deutsche Bank's price target for ISRG?
- Deutsche Bank's latest stated price target for Intuitive Surgical Inc. (ISRG) is $440, from its action on Jun 9, 2025.
- What is Deutsche Bank's rating on ISRG?
- Deutsche Bank rates ISRG Sell, a bearish rating, as of Jun 9, 2025.
- When did Deutsche Bank last change its view on ISRG?
- On Jun 9, 2025, Deutsche Bank downgrades to Sell from Hold, price target $440.
- How does Deutsche Bank's ISRG target compare with other analysts?
- Across 7 firms with a ISRG price target in the last 12 months, the median target is $500.
More ISRG rating histories
- Erste Group3
- UBS5
- Citigroup7
- Morgan Stanley7
- Evercore ISI3
- BTIG3
- Stifel4
- Wells Fargo4
- BofA Securities3
- Piper Sandler3
All Deutsche Bank ratingsISRG news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.